UNSPSC 51422359: Paramethasone disodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41I31208JK, chemically known as pregna-1,4-diene-3,20-dione, 6-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as paramethasone disodium phosphate, which bears US NIH Compound Identifier 16509.

European Medicines Agency schedules paramethasone disodium phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09614MIG. Most nations, for tariff purposes, schedule paramethasone disodium phosphate under HS 29372200. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)C)F.[NA+].[NA+].

UNSPSC 51422359 Paramethasone disodium phosphate is a Commodity code with minimal recent state and local procurement activity aligned to its nominal pharmaceutical scope. The two opportunities posted under this code in the past three months diverge significantly from the code's clinical steroid medication classification: Seminole County, Florida issued an IFB for Naloxone and Safe Drug Deactivation Systems (opioid-reversal agents and harm-reduction equipment), and the Texas Health and Human Services Commission issued a Request for Information regarding direct-to-manufacturer prescription programs without specifying drug categories or active pharmaceutical ingredients. State and local buyers using this code appear to span county health departments and state health agencies, though the sample is too small and misaligned to establish a meaningful issuing-body pattern.

Activity is concentrated in the South—Florida and Texas posted the only recent opportunities—with no discernible geographic spread across other regions. Seminole County's IFB (posted June 30, 2026, due July 26, 2026) sought quarterly deliveries of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems to the Seminole County Community Health Building under a two-year initial term with a one-year renewal option; the solicitation required electronic bid submission, E-Verify compliance, and workers' compensation and commercial general liability insurance. The Texas HHS Commission's RFI (posted April 3, 2026) gathered vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels, framed as exploratory market research rather than a binding procurement. The code's sparse and off-topic activity suggests limited current relevance for firms targeting state and local pharmaceutical procurement in this category.